581 related articles for article (PubMed ID: 27628323)
1. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
[TBL] [Abstract][Full Text] [Related]
2. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.
Kim DS; Jang GC; Cha SH; Choi SH; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Bang J; Naimi Z; Bouckenooghe A; Bosch-Castells V; Houillon G
Pediatr Infect Dis J; 2016 Feb; 35(2):e60-4. PubMed ID: 26535878
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E
Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833
[TBL] [Abstract][Full Text] [Related]
5. Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety.
Feroldi E; Pancharoen C; Kosalaraksa P; Chokephaibulkit K; Boaz M; Meric C; Hutagalung Y; Bouckenooghe A
Pediatr Infect Dis J; 2014 Jun; 33(6):643-9. PubMed ID: 24717964
[TBL] [Abstract][Full Text] [Related]
6. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
[TBL] [Abstract][Full Text] [Related]
7. Immunizing children aged 9 to 15 months with live attenuated SA14-14-2 Japanese encephalitis vaccine in Thailand.
Chotpitayasunondh T; Sohn YM; Yoksan S; Min J; Ohrr H
J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S195-203. PubMed ID: 22043776
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine.
Wijesinghe PR; Abeysinghe MRN; Yoksan S; Yao Y; Zhou B; Zhang L; Fleming JA; Marfin AA; Victor JC
Vaccine; 2016 Nov; 34(48):5923-5928. PubMed ID: 27773472
[TBL] [Abstract][Full Text] [Related]
9. Long-term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization.
Kosalaraksa P; Watanaveeradej V; Pancharoen C; Capeding MR; Feroldi E; Bouckenooghe A
Pediatr Infect Dis J; 2017 Apr; 36(4):e108-e113. PubMed ID: 28030526
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a single dose of a live attenuated Japanese encephalitis chimeric virus vaccine in Vietnam: A single-arm, single-center study.
Vu TD; Nguyen QD; Tran HTA; Bosch-Castells V; Zocchetti C; Houillon G
Int J Infect Dis; 2018 Jan; 66():137-142. PubMed ID: 29081368
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.
Chanthavanich P; Limkittikul K; Sirivichayakul C; Chokejindachai W; Hattasingh W; Pengsaa K; Surangsrirat S; Srisuwannaporn T; Kaewma B; Yoksan S; Jun G; Zhumu B
Hum Vaccin Immunother; 2018 Apr; 14(4):900-905. PubMed ID: 29227177
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of a Live Attenuated Chimeric Japanese Encephalitis Vaccine as a Booster Dose After Primary Vaccination With Live Attenuated SA14-14-2 Vaccine: A Phase IV Study in Thai Children.
Sricharoenchai S; Lapphra K; Chuenkitmongkol S; Phongsamart W; Bouckenooghe A; Wittawatmongkol O; Rungmaitree S; Chokephaibulkit K
Pediatr Infect Dis J; 2017 Feb; 36(2):e45-e47. PubMed ID: 27846060
[TBL] [Abstract][Full Text] [Related]
13. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis.
Paulke-Korinek M; Kollaritsch H; Kundi M; Zwazl I; Seidl-Friedrich C; Jelinek T
Vaccine; 2015 Jul; 33(30):3600-4. PubMed ID: 26036947
[TBL] [Abstract][Full Text] [Related]
14. Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children.
Feroldi E; Capeding MR; Boaz M; Gailhardou S; Meric C; Bouckenooghe A
Hum Vaccin Immunother; 2013 Apr; 9(4):889-97. PubMed ID: 23442823
[TBL] [Abstract][Full Text] [Related]
15. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
16. Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial.
Feroldi E; Pancharoen C; Kosalaraksa P; Watanaveeradej V; Phirangkul K; Capeding MR; Boaz M; Gailhardou S; Bouckenooghe A
Hum Vaccin Immunother; 2012 Jul; 8(7):929-37. PubMed ID: 22777096
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children.
Chokephaibulkit K; Houillon G; Feroldi E; Bouckenooghe A
Expert Rev Vaccines; 2016; 15(2):153-66. PubMed ID: 26588242
[TBL] [Abstract][Full Text] [Related]
18. Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccine.
Bouckenooghe A; Bailleux F; Feroldi E
Hum Vaccin Immunother; 2019; 15(1):72-79. PubMed ID: 30230947
[TBL] [Abstract][Full Text] [Related]
19. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.
Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
Vaccine; 2013 Dec; 32(1):119-23. PubMed ID: 24176496
[TBL] [Abstract][Full Text] [Related]
20. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
